Nifty
Sensex
:
:
17149.10
57491.51
-468.05 (-2.66%)
-1545.67 (-2.62%)

Pharmaceuticals & Drugs - Global

Rating :
42/99

BSE: 500257 | NSE: LUPIN

903.40
21-Jan-2022
  • Open
  • High
  • Low
  • Previous Close
  •  937.45
  •  937.95
  •  897.60
  •  939.50
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1198180
  •  10949.00
  •  1267.65
  •  853.50

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 41,034.42
  • N/A
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 44,074.94
  • 0.72%
  • 3.43

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.81%
  • 0.76%
  • 9.98%
  • FII
  • DII
  • Others
  • 15.28%
  • 24.90%
  • 2.27%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.91
  • -2.82
  • -3.27

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.92
  • -10.59
  • -0.78

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 3.52
  • -13.61
  • 26.10

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 26.13
  • 22.23
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.73
  • 3.16
  • 3.09

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.79
  • 15.63
  • 17.09

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 21
Sep 20
Var%
Jun 21
Jun 20
Var%
Mar 21
Mar 20
Var%
Dec 20
Dec 19
Var%
Net Sales
4,091.33
3,835.00
6.68%
4,270.19
3,527.86
21.04%
3,783.10
3,845.74
-1.63%
4,017.36
3,769.27
6.58%
Expenses
5,415.18
3,253.83
66.42%
3,342.62
3,039.78
9.96%
3,075.55
3,320.42
-7.37%
3,238.62
3,340.17
-3.04%
EBITDA
-1,323.85
581.17
-
927.57
488.08
90.04%
707.55
525.32
34.69%
778.74
429.10
81.48%
EBIDTM
-32.36%
15.15%
21.72%
13.84%
18.70%
13.66%
19.38%
11.38%
Other Income
72.81
24.96
191.71%
64.99
43.28
50.16%
58.22
208.60
-72.09%
21.17
93.59
-77.38%
Interest
34.43
33.62
2.41%
33.47
44.26
-24.38%
31.84
107.38
-70.35%
30.92
88.60
-65.10%
Depreciation
919.33
212.73
332.16%
208.76
214.64
-2.74%
215.72
214.26
0.68%
244.32
253.23
-3.52%
PBT
-2,204.80
359.78
-
750.33
272.46
175.39%
518.21
495.37
4.61%
524.67
-107.82
-
Tax
-109.91
146.70
-
202.33
164.32
23.13%
54.01
105.07
-48.60%
83.49
767.02
-89.12%
PAT
-2,094.89
213.08
-
548.00
108.14
406.75%
464.20
390.30
18.93%
441.18
-874.84
-
PATM
-51.20%
5.56%
12.83%
3.07%
12.27%
10.15%
10.98%
-23.21%
EPS
-46.21
4.66
-
11.95
2.36
406.36%
10.15
8.60
18.02%
9.66
-18.44
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Net Sales
16,161.98
15,162.96
16,836.56
16,751.37
15,804.15
17,494.33
14,139.03
12,770.01
11,286.57
9,641.30
7,082.91
Net Sales Growth
7.91%
-9.94%
0.51%
5.99%
-9.66%
23.73%
10.72%
13.14%
17.06%
36.12%
 
Cost Of Goods Sold
5,847.04
4,854.28
4,962.72
4,436.67
4,733.76
4,660.97
3,893.70
3,806.16
3,485.50
3,221.50
2,364.87
Gross Profit
10,314.94
10,308.68
11,873.84
12,314.70
11,070.39
12,833.36
10,245.33
8,963.85
7,801.07
6,419.80
4,718.04
GP Margin
63.82%
67.99%
70.52%
73.51%
70.05%
73.36%
72.46%
70.19%
69.12%
66.59%
66.61%
Total Expenditure
15,071.97
12,596.08
14,362.21
14,082.44
12,656.64
13,001.19
10,453.68
9,150.42
8,283.78
7,371.41
5,638.20
Power & Fuel Cost
-
414.48
443.17
442.28
433.88
377.86
381.27
362.81
334.29
320.22
268.82
% Of Sales
-
2.73%
2.63%
2.64%
2.75%
2.16%
2.70%
2.84%
2.96%
3.32%
3.80%
Employee Cost
-
2,825.90
2,986.84
2,770.17
2,864.71
2,849.52
2,141.62
1,747.34
1,464.65
1,266.62
969.53
% Of Sales
-
18.64%
17.74%
16.54%
18.13%
16.29%
15.15%
13.68%
12.98%
13.14%
13.69%
Manufacturing Exp.
-
1,945.67
1,852.21
1,731.57
2,087.52
2,270.19
1,766.00
1,320.55
1,129.59
976.51
753.07
% Of Sales
-
12.83%
11.00%
10.34%
13.21%
12.98%
12.49%
10.34%
10.01%
10.13%
10.63%
General & Admin Exp.
-
1,218.42
1,456.46
3,302.60
1,219.96
1,509.56
1,195.98
806.87
810.53
692.06
471.23
% Of Sales
-
8.04%
8.65%
19.72%
7.72%
8.63%
8.46%
6.32%
7.18%
7.18%
6.65%
Selling & Distn. Exp.
-
1,026.40
1,080.45
1,206.60
1,150.61
1,049.48
870.29
835.48
775.26
709.62
647.88
% Of Sales
-
6.77%
6.42%
7.20%
7.28%
6.00%
6.16%
6.54%
6.87%
7.36%
9.15%
Miscellaneous Exp.
-
310.93
1,580.36
192.55
166.20
283.61
204.82
271.21
283.96
184.88
647.88
% Of Sales
-
2.05%
9.39%
1.15%
1.05%
1.62%
1.45%
2.12%
2.52%
1.92%
2.30%
EBITDA
1,090.01
2,566.88
2,474.35
2,668.93
3,147.51
4,493.14
3,685.35
3,619.59
3,002.79
2,269.89
1,444.71
EBITDA Margin
6.74%
16.93%
14.70%
15.93%
19.92%
25.68%
26.07%
28.34%
26.60%
23.54%
20.40%
Other Income
217.19
136.29
483.76
333.01
150.35
106.51
185.19
239.75
116.48
27.85
14.35
Interest
130.66
140.64
362.98
302.49
204.35
152.53
59.47
9.81
26.65
40.95
35.47
Depreciation
1,588.13
887.41
970.22
846.05
1,085.87
912.23
487.13
434.70
260.97
332.19
227.52
PBT
-411.59
1,675.12
1,624.91
1,853.40
2,007.64
3,534.89
3,323.94
3,414.83
2,831.65
1,924.60
1,196.07
Tax
229.92
448.52
1,146.56
901.69
288.46
978.51
1,059.34
970.40
962.15
584.16
308.56
Tax Rate
-55.86%
26.78%
131.36%
59.58%
53.10%
27.68%
31.87%
28.42%
33.98%
30.35%
25.80%
PAT
-641.51
1,226.60
-273.72
611.73
247.74
2,549.21
2,255.84
2,403.24
1,836.37
1,314.16
867.65
PAT before Minority Interest
-657.49
1,226.60
-273.72
611.73
254.83
2,556.38
2,264.60
2,444.43
1,869.50
1,340.44
887.51
Minority Interest
-15.98
0.00
0.00
0.00
-7.09
-7.17
-8.76
-41.19
-33.13
-26.28
-19.86
PAT Margin
-3.97%
8.09%
-1.63%
3.65%
1.57%
14.57%
15.95%
18.82%
16.27%
13.63%
12.25%
PAT Growth
0.00%
-
-
146.92%
-90.28%
13.00%
-6.13%
30.87%
39.74%
51.46%
 
EPS
-14.12
27.01
-6.03
13.47
5.45
56.13
49.67
52.91
40.43
28.93
19.10

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Shareholder's Funds
13,803.14
12,536.70
13,742.23
13,577.06
13,497.57
11,163.37
8,874.06
6,931.57
5,204.18
4,012.89
Share Capital
90.74
90.60
90.50
90.42
90.32
90.12
89.90
89.68
89.51
89.33
Total Reserves
13,522.87
12,231.40
13,433.31
13,275.26
13,233.50
10,958.87
8,728.15
6,815.66
5,107.79
3,920.76
Non-Current Liabilities
1,136.03
3,003.18
7,296.41
6,876.13
6,446.96
6,032.39
426.15
507.16
572.87
729.96
Secured Loans
0.33
0.70
358.82
448.03
217.15
5.55
12.50
24.42
37.95
27.76
Unsecured Loans
15.79
1,792.58
6,282.90
5,976.47
5,430.63
5,368.35
89.33
126.54
209.11
405.20
Long Term Provisions
329.49
296.29
370.79
356.85
308.73
190.00
162.03
132.49
112.45
77.02
Current Liabilities
8,436.09
9,225.20
6,129.87
5,095.55
6,120.59
5,061.17
3,729.23
2,629.55
3,006.92
3,120.30
Trade Payables
2,014.44
2,412.30
2,498.18
2,575.40
2,588.90
1,988.82
1,956.06
1,594.13
1,542.88
1,379.28
Other Current Liabilities
2,451.01
3,124.23
1,279.82
1,517.16
657.97
1,001.27
829.76
287.64
381.25
377.17
Short Term Borrowings
3,049.44
2,492.75
1,580.21
451.76
2,304.33
1,745.41
369.15
402.38
726.82
1,046.99
Short Term Provisions
921.20
1,195.92
771.66
551.23
569.39
325.67
574.26
345.40
355.97
316.86
Total Liabilities
23,430.23
24,809.54
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22
8,843.42
7,935.44
Net Block
7,880.76
7,938.11
11,086.71
10,361.99
11,032.93
8,716.96
4,368.19
3,355.60
3,000.17
2,749.66
Gross Block
14,726.75
14,160.50
15,731.88
13,859.86
12,395.30
9,212.07
6,644.59
5,283.90
4,684.21
4,191.84
Accumulated Depreciation
6,845.99
6,222.39
4,645.17
3,497.87
1,362.37
495.11
2,276.40
1,928.30
1,684.04
1,442.18
Non Current Assets
9,443.86
9,396.33
13,361.79
13,379.28
14,146.71
12,401.61
5,221.19
4,034.77
3,700.29
3,593.12
Capital Work in Progress
1,066.26
939.62
1,639.71
2,598.20
2,133.06
2,702.40
551.87
285.90
310.70
434.84
Non Current Investment
78.07
36.07
185.63
26.71
22.00
14.33
2.51
2.06
2.06
2.80
Long Term Loans & Adv.
405.79
409.58
402.61
383.00
950.76
960.22
274.20
372.99
387.36
396.94
Other Non Current Assets
12.98
72.95
47.13
9.38
7.96
7.70
0.32
0.00
0.00
0.00
Current Assets
13,986.37
15,413.21
13,853.58
12,209.54
11,952.93
9,887.40
7,832.35
6,100.45
5,143.13
4,342.32
Current Investments
2,376.81
2,338.25
2,109.86
234.86
2,114.13
2.02
1,655.89
176.41
0.00
0.00
Inventories
4,092.01
3,456.87
3,836.77
3,662.49
3,642.28
3,273.65
2,503.56
2,129.45
1,948.93
1,732.67
Sundry Debtors
4,474.32
5,445.93
5,149.80
5,192.21
4,307.34
4,548.76
2,656.57
2,464.10
2,186.99
1,780.01
Cash & Bank
1,742.46
2,454.30
987.20
1,408.03
698.17
821.75
481.35
797.50
434.88
402.47
Other Current Assets
1,300.77
537.33
777.47
621.30
1,191.01
1,241.22
534.98
532.99
572.33
427.17
Short Term Loans & Adv.
743.88
1,180.53
992.48
1,090.65
657.58
761.78
294.91
275.15
339.67
306.12
Net Current Assets
5,550.28
6,188.01
7,723.71
7,113.99
5,832.34
4,826.23
4,103.12
3,470.90
2,136.21
1,222.02
Total Assets
23,430.23
24,809.54
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22
8,843.42
7,935.44

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Cash From Operating Activity
1,821.76
1,468.84
1,665.97
1,751.19
4,113.51
-382.39
2,733.05
2,003.93
1,250.96
560.04
PBT
1,676.45
876.78
1,517.17
546.81
3,543.14
3,328.84
3,414.83
2,831.65
1,924.60
1,196.07
Adjustment
1,053.31
1,574.29
1,588.41
2,782.23
1,214.74
585.35
356.73
410.50
419.58
258.51
Changes in Working Capital
-192.49
-471.02
-500.19
-1,019.43
504.62
-3,126.44
-94.91
-466.31
-549.35
-580.65
Cash after chg. in Working capital
2,537.27
1,980.05
2,605.39
2,309.61
5,262.50
787.75
3,676.65
2,775.84
1,794.83
873.93
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-715.51
-511.21
-939.42
-558.42
-1,148.99
-1,170.14
-943.60
-771.91
-543.87
-313.89
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,239.58
1,106.99
-3,282.47
469.87
-2,527.44
-6,961.71
-1,054.51
-858.54
-521.86
-741.25
Net Fixed Assets
-693.00
-481.49
-462.56
-1,394.31
-876.24
480.96
-416.45
-309.36
-324.79
-389.71
Net Investments
-2,106.15
-67.96
-2,025.62
1,551.07
-3,173.10
-296.59
-2,280.57
-475.62
-0.75
-6.41
Others
1,559.57
1,656.44
-794.29
313.11
1,521.90
-7,146.08
1,642.51
-73.56
-196.32
-345.13
Cash from Financing Activity
-1,885.27
-890.58
744.13
-1,492.10
433.18
5,836.38
-196.89
-857.11
-662.82
108.86
Net Cash Inflow / Outflow
-1,303.09
1,685.25
-872.37
728.96
2,019.25
-1,507.72
1,481.65
288.28
66.28
-72.35
Opening Cash & Equivalents
2,229.31
544.06
1,416.43
687.47
780.22
2,095.06
606.62
310.93
244.65
295.88
Closing Cash & Equivalent
926.22
2,229.31
544.06
1,416.43
2,799.47
780.22
2,108.43
606.62
310.93
244.65

Financial Ratios

Consolidated /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Book Value (Rs.)
300.06
272.01
298.87
295.64
295.04
245.21
196.17
154.00
116.13
89.78
ROA
5.09%
-1.05%
2.32%
0.99%
10.57%
12.82%
21.08%
19.70%
15.98%
12.40%
ROE
9.46%
-2.12%
4.55%
1.91%
20.98%
22.80%
31.09%
30.89%
29.12%
24.35%
ROCE
9.70%
6.02%
8.45%
3.54%
18.53%
24.38%
40.30%
40.97%
32.70%
24.40%
Fixed Asset Turnover
1.96
2.10
1.93
2.07
1.63
1.80
2.16
2.28
2.19
1.99
Receivable days
64.06
61.62
66.11
63.76
91.82
92.24
72.65
74.67
74.61
77.76
Inventory Days
48.75
42.41
47.94
49.03
71.70
73.96
65.73
65.48
69.24
75.12
Payable days
62.54
65.89
68.49
68.56
60.60
63.20
64.43
63.78
63.76
64.11
Cash Conversion Cycle
50.26
38.14
45.56
44.23
102.92
103.00
73.94
76.37
80.10
88.76
Total Debt/Equity
0.35
0.51
0.63
0.53
0.60
0.65
0.06
0.09
0.22
0.41
Interest Cover
12.91
3.40
6.00
3.66
24.18
56.89
349.10
107.25
48.00
34.72

News Update:


  • Lupin enters into partnership with Shenzhen Foncoo Pharmaceutical
    19th Jan 2022, 10:29 AM

    This is Lupin’s first partnership arrangement in China

    Read More
  • Lupin gets nod to acquire portfolio of brands of Anglo-French Drugs & Industries
    18th Jan 2022, 14:02 PM

    The Board of Directors of the company at its meeting held on January 17, 2022, approved the same

    Read More
  • Lupin recalling 50,832 bottles of Gatifloxacin Ophthalmic Solution
    17th Jan 2022, 11:27 AM

    The company is also recalling 23,965 bottles of Oxycodone Hydrochloride tablets

    Read More
  • Lupin launches Molnupiravir under brand name ‘Molnulup’
    7th Jan 2022, 09:09 AM

    This drug has been given emergency use authorization by the DCGI for treatment of adult patients with Covid19

    Read More
  • Lupin receives approval from USFDA for Sevelamer Carbonate for Oral Suspension
    27th Dec 2021, 09:12 AM

    This product will be manufactured at Lupin's Goa facility in India

    Read More
  • Lupin gets tentative approval from USFDA for Azilsartan Medoxomil Tablets
    24th Dec 2021, 10:10 AM

    This product will be manufactured at Lupin's Nagpur facility in India

    Read More
  • Lupin’s Goa manufacturing facility gets EIR from USFDA
    14th Dec 2021, 10:23 AM

    The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated

    Read More
  • Lupin recalls generic oral contraceptive tablets in US
    13th Dec 2021, 09:57 AM

    The company is recalling the lot due to it being Subpotent Drug

    Read More
  • Lupin launches diagnostics business in India
    10th Dec 2021, 14:27 PM

    As part of its strategy to provide integrated healthcare in India, Lupin Diagnostics, a wholly owned subsidiary of Lupin has formally commenced operations

    Read More
  • Lupin enters into distribution and marketing agreement with Biomm SA
    4th Dec 2021, 10:07 AM

    Pegfilgrastim is indicated to reduce the duration of neutropenia and the Incidence of febrile neutropenia in patients receiving chemotherapy

    Read More
  • Lupin’s arm enters into agreement with TTP pie
    2nd Dec 2021, 11:28 AM

    The company has entered into an agreement to acquire the exclusive worldwide rights to develop, manufacture and commercialize Inhalation products using TTP's soft-mist inhalation technology platform

    Read More
  • Lupin launches mobile-friendly learning platform ‘Sciflix’ for post graduate students
    30th Nov 2021, 10:37 AM

    Sciflix is a special Initiative by Lupin to assist future pulmonologists in staying abreast of the latest medical advances relevant to their specialty

    Read More
  • Lupin’s consumer healthcare business wins best packaging design, graphics, brand value add award
    9th Nov 2021, 09:50 AM

    This award is an initiative by Informa Markets in India to honour the best branding initiatives from the pharma packaging space

    Read More
  • Lupin recalling 16,272 bottles of Gatifloxacin Ophthalmic Solution in US market
    8th Nov 2021, 10:36 AM

    Out-of-specification results observed in a water loss test that might affect the assay content and alter drug concentration

    Read More
  • Lupin reports consolidated net loss of Rs 2098 crore in Q2
    28th Oct 2021, 12:01 PM

    Total consolidated income of the company increased by 7.88% at Rs 4164.14 crore for Q2FY22

    Read More
  • Lupin - Quarterly Results
    27th Oct 2021, 23:04 PM

    Read More
  • Lupinlife ropes in Hrithik Roshan as brand ambassador for Be One, Ayurvedic Energy Supplement
    22nd Oct 2021, 12:57 PM

    Be One is a scientifically tested supplement with the goodness of eight Ayurvedic ingredients like Ashwagandha, Pippali and Shatavari in a single vegetarian capsule

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.